Valory N. Pavlik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valory N. Pavlik has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Susan D. Rountree
Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
4 shared publications - Wenyaw Chan
Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
4 shared publications - Eveleen Darby
Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA
3 shared publications Rachelle Doody
Product Development Neuroscience, F. Hoffmann-La Roche Ltd, Basel, Switzerland
3 shared publications- Rachelle S. Doody
Baylor College of Medicine, Houston, TX, USA
3 shared publications Wenyaw Chan
University of Texas School of Public Health–Houston Houston TX USA
3 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
Plasma Phosphorylated Tau 217 Reshapes Diagnostic Classification in a Real-World Memory Clinic Cohort
Background: Plasma phosphorylated tau-217 (ptau217) accurately identifies Alzheimer disease (AD), but its impact on real-world clinical diagnosis remains unclear. We evaluated the effect of plasma ptau217 on diagnostic reclassification in a memory disorders clinic. Methods: We retrospectively reviewed 100 patients evaluated for memory impairment. Initial clinical diagnoses were established based on clinical evaluation, neuropsychological testing, and brain MRI without plasma biomarker results. Follow-up diagnoses were assigned after the availability of plasma ptau217 results. Diagnostic reclassification was assessed using binary (ptau217 > 0.18) and higher threshold (ptau217 > 0.325) classification schemes. McNemar tests evaluated reclassification patterns, with subgroup analyses by apolipoprotein E ( APOE) ε4 carrier status. Results: Diagnosis reclassification occurred in 37.8% and 46.9% of patients using the lower and higher threshold, respectively (both P 0.325), reclassification among APOE ε4 carriers was balanced (42% from AD to non-AD vs. 43% from non-AD to AD, P =0.096). In contrast, APOE ε4 noncarriers showed significantly greater reclassification from AD to non-AD than from non-AD to AD (66% vs.14%, P APOE ε4 noncarriers.
- 20 October 2026
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
Plasma Phosphorylated Tau 217 Reshapes Diagnostic Classification in a Real-World Memory Clinic Cohort
Background: Plasma phosphorylated tau-217 (ptau217) accurately identifies Alzheimer disease (AD), but its impact on real-world clinical diagnosis remains unclear. We evaluated the effect of plasma ptau217 on diagnostic reclassification in a memory disorders clinic. Methods: We retrospectively reviewed 100 patients evaluated for memory impairment. Initial clinical diagnoses were established based on clinical evaluation, neuropsychological testing, and brain MRI without plasma biomarker results. Follow-up diagnoses were assigned after the availability of plasma ptau217 results. Diagnostic reclassification was assessed using binary (ptau217 > 0.18) and higher threshold (ptau217 > 0.325) classification schemes. McNemar tests evaluated reclassification patterns, with subgroup analyses by apolipoprotein E ( APOE) ε4 carrier status. Results: Diagnosis reclassification occurred in 37.8% and 46.9% of patients using the lower and higher threshold, respectively (both P 0.325), reclassification among APOE ε4 carriers was balanced (42% from AD to non-AD vs. 43% from non-AD to AD, P =0.096). In contrast, APOE ε4 noncarriers showed significantly greater reclassification from AD to non-AD than from non-AD to AD (66% vs.14%, P APOE ε4 noncarriers.
- Open Access
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e104493
Cognitive Reserve is Associated with Entorhinal Cortex Tau Burden in an Older, Cognitively Unimpaired Clinical Trial Cohort (U.S. POINTER)
Background: High cognitive reserve (CR) is associated with a reduced dementia risk. and better cognitive performance for given levels of Alzheimer's disease (AD) pathology. We hypothesized that CR is associated with baseline amyloid and tau pathology in the U . S . Study to P r o tect Brain Health through Lifestyle Inte rvention to R educe Risk (U.S.POINTER) Trial cohort. Method: Participants were 60 to 79 years old, cognitively unimpaired, sedentary, did not follow a Mediterranean‐DASH (MIND) diet, and had two or more other dementia risk factors. Of 2011 randomized, 52% consented to an ancillary imaging study that included amyloid and tau positron emission tomography (PET). Odds ratios (OR) and beta coefficients from logistic regression and linear regression models respectively were calculated to test whether higher EDU, an accepted CR measure, predicted lower risk of amyloid positivity, and lower entorhinal cortex (ERC) and meta‐temporal region of interest (meta‐ROI) tau standardized uptake value ratio (SUVR). Models were adjusted for age, sex, race/ethnicity, family history of dementia, APOE genotype, metabolic, dietary and physical fitness measures, and U.S.POINTER site. Result: 911 U.S.POINTER imaging study participants had complete imaging data. Mean age was 68.4 ±5.24 years, 61.3% were female, 31.5% completed only high school (HS), 34.6% were college graduates (CG), 33.9% had advanced degrees (AdD) and 29.2% were amyloid positive on PET. Predictors of amyloid positivity included age (OR=1.09 1‐year increment , 95% CI = .06,1.13, p < .001), race‐ethnicity (1.67 white vs black/AA , 95% CI=0.99‐2.82, p = .054; 2.31 other vs black/AA, 95% CI=1.10, 4.84, p = .024), number of APOE e4 alleles (OR 1 copy =3.01, 95% CI=2.16, 4.19, p < .001; OR 2 copies =10.66, 95% CI = 4.40, 25.82, p < .001), and memory loss in mother (OR=1.47, 95% CI=1.06,2.04, p = .020). Higher CR was significantly associated with lower ERC tau SUVR (Beta CG vs HS = ‐.047±.02, p = .038; Beta AdD vs HS = ‐.068±.023, p = .003). EDU was unrelated to amyloid status or meta‐ROI tau. Conclusion: In the U.S.POINTER Cohort, higher CR predicted lower tau burden in the ERC, a brain area first affected by tau deposition. Meta‐ROI tau may be too low in this cognitively unimpaired sample to reveal associations. The findings suggest a possible role of CR in conferring biological resistance to AD pathology.
- 25 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S3) , e104493
Open AccessCognitive Reserve is Associated with Entorhinal Cortex Tau Burden in an Older, Cognitively Unimpaired Clinical Trial Cohort (U.S. POINTER)
Background: High cognitive reserve (CR) is associated with a reduced dementia risk. and better cognitive performance for given levels of Alzheimer's disease (AD) pathology. We hypothesized that CR is associated with baseline amyloid and tau pathology in the U . S . Study to P r o tect Brain Health through Lifestyle Inte rvention to R educe Risk (U.S.POINTER) Trial cohort. Method: Participants were 60 to 79 years old, cognitively unimpaired, sedentary, did not follow a Mediterranean‐DASH (MIND) diet, and had two or more other dementia risk factors. Of 2011 randomized, 52% consented to an ancillary imaging study that included amyloid and tau positron emission tomography (PET). Odds ratios (OR) and beta coefficients from logistic regression and linear regression models respectively were calculated to test whether higher EDU, an accepted CR measure, predicted lower risk of amyloid positivity, and lower entorhinal cortex (ERC) and meta‐temporal region of interest (meta‐ROI) tau standardized uptake value ratio (SUVR). Models were adjusted for age, sex, race/ethnicity, family history of dementia, APOE genotype, metabolic, dietary and physical fitness measures, and U.S.POINTER site. Result: 911 U.S.POINTER imaging study participants had complete imaging data. Mean age was 68.4 ±5.24 years, 61.3% were female, 31.5% completed only high school (HS), 34.6% were college graduates (CG), 33.9% had advanced degrees (AdD) and 29.2% were amyloid positive on PET. Predictors of amyloid positivity included age (OR=1.09 1‐year increment , 95% CI = .06,1.13, p < .001), race‐ethnicity (1.67 white vs black/AA , 95% CI=0.99‐2.82, p = .054; 2.31 other vs black/AA, 95% CI=1.10, 4.84, p = .024), number of APOE e4 alleles (OR 1 copy =3.01, 95% CI=2.16, 4.19, p < .001; OR 2 copies =10.66, 95% CI = 4.40, 25.82, p < .001), and memory loss in mother (OR=1.47, 95% CI=1.06,2.04, p = .020). Higher CR was significantly associated with lower ERC tau SUVR (Beta CG vs HS = ‐.047±.02, p = .038; Beta AdD vs HS = ‐.068±.023, p = .003). EDU was unrelated to amyloid status or meta‐ROI tau. Conclusion: In the U.S.POINTER Cohort, higher CR predicted lower tau burden in the ERC, a brain area first affected by tau deposition. Meta‐ROI tau may be too low in this cognitively unimpaired sample to reveal associations. The findings suggest a possible role of CR in conferring biological resistance to AD pathology.
- Open Access
- 10 November 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (11) , e70892
Cognitive reserve predicts baseline tau burden in the U.S. POINTER trial imaging cohort
INTRODUCTION: Higher cognitive reserve (CR) is associated with reduced dementia risk. We hypothesized that higher CR is associated with less baseline Alzheimer's disease (AD) pathology in the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort. METHODS: A subsample of participants underwent amyloid beta and tau positron emission tomography imaging. Regression analysis was used to model the association between educational attainment (EA) as a CR proxy measure, amyloid positivity, and entorhinal cortex (ERC) and meta‐temporal region of interest (meta‐ROI) tau standardized uptake value ratio (SUVR). RESULTS: In 911 participants with complete imaging data, higher CR was significantly associated with lower ERC tau SUVR. CR was not associated with amyloid status or meta‐ROI tau. DISCUSSION: In the U.S. POINTER cohort, higher EA predicted lower tau burden in the ERC. Meta‐ROI tau levels may be too low in this cognitively unimpaired sample to reveal associations. CR may have a role in promoting biological resistance to AD pathology. Highlights: Higher cognitive reserve is associated with a lower dementia risk and better cognitive performance after a diagnosis of Alzheimer's disease. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk trial imaging cohort was cognitively unimpaired at baseline and a subsample received amyloid and tau positron emission tomography scans. Higher educational attainment, a proxy measure of cognitive reserve, was significantly related to tau levels in the entorhinal cortex region of interest.
- 10 November 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (11) , e70892
Open AccessCognitive reserve predicts baseline tau burden in the U.S. POINTER trial imaging cohort
INTRODUCTION: Higher cognitive reserve (CR) is associated with reduced dementia risk. We hypothesized that higher CR is associated with less baseline Alzheimer's disease (AD) pathology in the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) cohort. METHODS: A subsample of participants underwent amyloid beta and tau positron emission tomography imaging. Regression analysis was used to model the association between educational attainment (EA) as a CR proxy measure, amyloid positivity, and entorhinal cortex (ERC) and meta‐temporal region of interest (meta‐ROI) tau standardized uptake value ratio (SUVR). RESULTS: In 911 participants with complete imaging data, higher CR was significantly associated with lower ERC tau SUVR. CR was not associated with amyloid status or meta‐ROI tau. DISCUSSION: In the U.S. POINTER cohort, higher EA predicted lower tau burden in the ERC. Meta‐ROI tau levels may be too low in this cognitively unimpaired sample to reveal associations. CR may have a role in promoting biological resistance to AD pathology. Highlights: Higher cognitive reserve is associated with a lower dementia risk and better cognitive performance after a diagnosis of Alzheimer's disease. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk trial imaging cohort was cognitively unimpaired at baseline and a subsample received amyloid and tau positron emission tomography scans. Higher educational attainment, a proxy measure of cognitive reserve, was significantly related to tau levels in the entorhinal cortex region of interest.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e089646
Application of a Plasma Amyloid Beta Test in Clinical Practice
Background: The gold standard Alzheimer’s disease (AD) diagnosis with amyloid PET or CSF sampling is costly and not widely available. There is growing interest in utilizing plasma biomarker tests to provide etiologic clarity in the earliest symptomatic phases. We report the uptake, and biomarker results in relation to clinical diagnosis, of a brain amyloid probability score (APS) with the Precivity AD™ test (C2N Diagnostics) offered to clinician‐selected eligible patients during their clinical workup in a memory clinic.Method: Eligibility criteria included: MMSE>=22, a CDR global score <=1.0, and a diagnosis of subjective memory complaint (SMC), mild cognitive impairment (MCI) or early AD. Consensus clinical diagnoses were assigned according to NIA‐AA criteria prior to obtaining PrecivityAD™ results. The APS, derived from a regression equation including plasma Aß42/ 40, age, and APOE genotype, has a reported accuracy of 86%. To identify selection factors for referral, we used logistic regression to assess the independent association of age, sex, race/ethnicity, years of education, MMSE score, number of APOE e4 alleles, and diagnosis between participants and a sample of non‐participating patients meeting the same eligibility criteria.Result: Sixty patients were consented over 9 months. Average age was 70.8±8.06, 60.0% were male, and 11.3% persons of color. Fifty‐five percent of those with MCI received a high APS, compared to 15.4% of those with SMC. Forty‐one percent of MCI patients had a low APS compared to 61.5% with SMC (Table 1). Only a diagnosis of probable AD was associated with enrollment (less likely).Conclusion: PrecivityAD™ probability scores were generally consistent with the clinical diagnosis. An intermediate or high APS required clinician counselling regarding the implications of and indications for further testing given the clinical diagnosis. The high representation of SMC patients may reflect provider and/or patient desire for additional information on prognosis. The low usage in patients with probable AD may reflect a greater degree of provider certainty in clinical diagnosis. Longitudinal follow‐up of cognitive changes, and analysis of PET imaging results in those referred for additional testing will clarify the clinical utility of this plasma biomarker.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S2) , e089646
Open AccessApplication of a Plasma Amyloid Beta Test in Clinical Practice
Background: The gold standard Alzheimer’s disease (AD) diagnosis with amyloid PET or CSF sampling is costly and not widely available. There is growing interest in utilizing plasma biomarker tests to provide etiologic clarity in the earliest symptomatic phases. We report the uptake, and biomarker results in relation to clinical diagnosis, of a brain amyloid probability score (APS) with the Precivity AD™ test (C2N Diagnostics) offered to clinician‐selected eligible patients during their clinical workup in a memory clinic.Method: Eligibility criteria included: MMSE>=22, a CDR global score <=1.0, and a diagnosis of subjective memory complaint (SMC), mild cognitive impairment (MCI) or early AD. Consensus clinical diagnoses were assigned according to NIA‐AA criteria prior to obtaining PrecivityAD™ results. The APS, derived from a regression equation including plasma Aß42/ 40, age, and APOE genotype, has a reported accuracy of 86%. To identify selection factors for referral, we used logistic regression to assess the independent association of age, sex, race/ethnicity, years of education, MMSE score, number of APOE e4 alleles, and diagnosis between participants and a sample of non‐participating patients meeting the same eligibility criteria.Result: Sixty patients were consented over 9 months. Average age was 70.8±8.06, 60.0% were male, and 11.3% persons of color. Fifty‐five percent of those with MCI received a high APS, compared to 15.4% of those with SMC. Forty‐one percent of MCI patients had a low APS compared to 61.5% with SMC (Table 1). Only a diagnosis of probable AD was associated with enrollment (less likely).Conclusion: PrecivityAD™ probability scores were generally consistent with the clinical diagnosis. An intermediate or high APS required clinician counselling regarding the implications of and indications for further testing given the clinical diagnosis. The high representation of SMC patients may reflect provider and/or patient desire for additional information on prognosis. The low usage in patients with probable AD may reflect a greater degree of provider certainty in clinical diagnosis. Longitudinal follow‐up of cognitive changes, and analysis of PET imaging results in those referred for additional testing will clarify the clinical utility of this plasma biomarker.
- Open Access
- 4 January 2022
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 85 (1) , 31-45
Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer’s disease (AD) foster scientific exchange, generate insights, and contribute to the evolving clinical science in AD. A scientific working group was convened with invited investigators from established cohort studies in AD, in order to form a research collaboration network as a resource to address important research questions. The Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD) collaboration network was created to bring together global resources and expertise, to generate insights and improve understanding of the natural history of AD, to inform design of clinical trials in all disease stages, and to plan for optimal patient access to disease-modifying therapies once they become available. The network brings together expertise and data insights from 7 cohorts across Australia, Europe, and North America. Notably, the network includes populations recruited through memory clinics as well as population-based cohorts, representing observations from individuals across the AD spectrum. This report aims to introduce the CONCORD-AD network, providing an overview of the cohorts involved, reporting the common assessments used, and describing the key characteristics of the cohort populations. Cohort study designs and baseline population characteristics are compared, and available cognitive, functional, and neuropsychiatric symptom data, as well as the frequency of biomarker assessments, are summarized. Finally, the challenges and opportunities of cross-cohort studies in AD are discussed.
- 4 January 2022
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 85 (1) , 31-45
Open AccessConnecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer’s disease (AD) foster scientific exchange, generate insights, and contribute to the evolving clinical science in AD. A scientific working group was convened with invited investigators from established cohort studies in AD, in order to form a research collaboration network as a resource to address important research questions. The Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD) collaboration network was created to bring together global resources and expertise, to generate insights and improve understanding of the natural history of AD, to inform design of clinical trials in all disease stages, and to plan for optimal patient access to disease-modifying therapies once they become available. The network brings together expertise and data insights from 7 cohorts across Australia, Europe, and North America. Notably, the network includes populations recruited through memory clinics as well as population-based cohorts, representing observations from individuals across the AD spectrum. This report aims to introduce the CONCORD-AD network, providing an overview of the cohorts involved, reporting the common assessments used, and describing the key characteristics of the cohort populations. Cohort study designs and baseline population characteristics are compared, and available cognitive, functional, and neuropsychiatric symptom data, as well as the frequency of biomarker assessments, are summarized. Finally, the challenges and opportunities of cross-cohort studies in AD are discussed.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S6)
Different profiles of cognitive deficits predict progression rate in probable AD
Background: Heterogeneity in the pattern of cognitive deficits seen in probable AD patients is well recognized. Two reliably reproducible profiles are ones that have an extreme deficit in either visuo‐spatial (Vis‐D) or language (Lang‐D) domains compared to all other domains, independent of memory performance. Information on variability in progression rates and overall survival associated with these profiles is lacking.Method: Right handed probable AD patients followed longitudinally in a memory clinic, 50‐90 years old with baseline MMSE score ≥10, were classified as Vis‐D or Lang‐D if their scores on tests of visual and language function varied by ≥ 2 standard deviations. Proportional hazards analysis was used to compare time to reach an MMSE < 10, CDR global score=3, and survival time from diagnosis to death in Vis‐D, Lang‐D and balanced deficits (Bal‐D) groups, adjusting for age, sex, education, ethnicity, baseline co‐morbidity, and APOE genotype.Result: Of 540 patients meeting inclusion criteria, 86 (15.9%) were Vis‐D and 61 (11.3%) were Lang‐D. Median follow‐up time after baseline was 3.30 years (range 0.9, 13.3) and median time to death was 5.50 years (range=1.0, 16.8). The Vis‐D group was younger at diagnosis and had a higher prevalence of APOE e4 homozygosity than the Lang‐D and Bal‐D groups (69.8±8.5 vs 76.3±7.1 and 75.0±7.5 years and 25.9% vs 10.2% and 14.1% APOE e4 homozygosity respectively). Lang‐D patients reached a severe stage on the MMSE more rapidly than Vis‐D and Bal‐D (HRLang‐d vs Bal‐D=1.68, 95% CI=0.99‐2.73, p=.054; HRLang‐D vs Vis‐D=2.04, 95% CI=1.06‐3.78, p=.032). Results for the CDR endpoint were similar (HRLang‐D vs Bal‐D=1.64, 95% CI=1.04‐2.56, p=.032; HRLang‐D vs Vis‐D=2.32, 95%CI=1.40‐4.57, p=.002). Cognitive profile did not affect time to death.Conclusion: Probable AD patients with a Lang‐D cognitive profile decline faster on the MMSE and CDR than those with other cognitive profiles. Cognitive profile at diagnosis does not affect overall survival. Understanding the neuropathology underlying these cognitive profile differences could have implications for development or selection of disease modifying treatments.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S6)
Different profiles of cognitive deficits predict progression rate in probable AD
Background: Heterogeneity in the pattern of cognitive deficits seen in probable AD patients is well recognized. Two reliably reproducible profiles are ones that have an extreme deficit in either visuo‐spatial (Vis‐D) or language (Lang‐D) domains compared to all other domains, independent of memory performance. Information on variability in progression rates and overall survival associated with these profiles is lacking.Method: Right handed probable AD patients followed longitudinally in a memory clinic, 50‐90 years old with baseline MMSE score ≥10, were classified as Vis‐D or Lang‐D if their scores on tests of visual and language function varied by ≥ 2 standard deviations. Proportional hazards analysis was used to compare time to reach an MMSE < 10, CDR global score=3, and survival time from diagnosis to death in Vis‐D, Lang‐D and balanced deficits (Bal‐D) groups, adjusting for age, sex, education, ethnicity, baseline co‐morbidity, and APOE genotype.Result: Of 540 patients meeting inclusion criteria, 86 (15.9%) were Vis‐D and 61 (11.3%) were Lang‐D. Median follow‐up time after baseline was 3.30 years (range 0.9, 13.3) and median time to death was 5.50 years (range=1.0, 16.8). The Vis‐D group was younger at diagnosis and had a higher prevalence of APOE e4 homozygosity than the Lang‐D and Bal‐D groups (69.8±8.5 vs 76.3±7.1 and 75.0±7.5 years and 25.9% vs 10.2% and 14.1% APOE e4 homozygosity respectively). Lang‐D patients reached a severe stage on the MMSE more rapidly than Vis‐D and Bal‐D (HRLang‐d vs Bal‐D=1.68, 95% CI=0.99‐2.73, p=.054; HRLang‐D vs Vis‐D=2.04, 95% CI=1.06‐3.78, p=.032). Results for the CDR endpoint were similar (HRLang‐D vs Bal‐D=1.64, 95% CI=1.04‐2.56, p=.032; HRLang‐D vs Vis‐D=2.32, 95%CI=1.40‐4.57, p=.002). Cognitive profile did not affect time to death.Conclusion: Probable AD patients with a Lang‐D cognitive profile decline faster on the MMSE and CDR than those with other cognitive profiles. Cognitive profile at diagnosis does not affect overall survival. Understanding the neuropathology underlying these cognitive profile differences could have implications for development or selection of disease modifying treatments.
- 1 May 2017
- Published by Wolters Kluwer Health in Journal for Healthcare Quality
- Vol. 39 (3) , 153-167
Using a Mixed Methods Approach to Examine Practice Characteristics Associated With Implementation of an Adult Immunization Intervention Using the 4 Pillars Practice Transformation Program
Adult immunization rates are consistently suboptimal, exacting significant human and financial burden of preventable disease. Practice-level interventions to improve immunization rates have produced mixed results. The context of change critically affects implementation of evidence-based interventions. We conducted a randomized controlled cluster trial of the 4 Pillars Practice Transformation Program to increase adult vaccination rates in primary care practices and used qualitative methods to test intervention effects and understand practice characteristics associated with implementation success. We conducted qualitative interviews with staff from 14 practices to assess implementation experiences. Thematic analysis of data pointed to the importance of quality improvement history, communication and practice leadership, Immunization Champion leadership effectiveness, and organizational flexibility. Practices were scored on these characteristics and grouped into four types: Low Implementers, Medium Implementers, High Implementers, and Public/University Practices. Intervention uptake and immunization rate changes were compared, and a significant increase in influenza vaccination rates (3.9 percentage points [PPs]; p = .038) was observed for High Implementers only. Significant increases in Tdap vaccination rates were observed for High Implementers (9.3 PP; p = 0.006) and the Public/University groups (6.5 PP; p = 0.012), but not other groups. Practice characteristics may be critical factors in predicting intervention success.
- 1 May 2017
- Published by Wolters Kluwer Health in Journal for Healthcare Quality
- Vol. 39 (3) , 153-167
Using a Mixed Methods Approach to Examine Practice Characteristics Associated With Implementation of an Adult Immunization Intervention Using the 4 Pillars Practice Transformation Program
Adult immunization rates are consistently suboptimal, exacting significant human and financial burden of preventable disease. Practice-level interventions to improve immunization rates have produced mixed results. The context of change critically affects implementation of evidence-based interventions. We conducted a randomized controlled cluster trial of the 4 Pillars Practice Transformation Program to increase adult vaccination rates in primary care practices and used qualitative methods to test intervention effects and understand practice characteristics associated with implementation success. We conducted qualitative interviews with staff from 14 practices to assess implementation experiences. Thematic analysis of data pointed to the importance of quality improvement history, communication and practice leadership, Immunization Champion leadership effectiveness, and organizational flexibility. Practices were scored on these characteristics and grouped into four types: Low Implementers, Medium Implementers, High Implementers, and Public/University Practices. Intervention uptake and immunization rate changes were compared, and a significant increase in influenza vaccination rates (3.9 percentage points [PPs]; p = .038) was observed for High Implementers only. Significant increases in Tdap vaccination rates were observed for High Implementers (9.3 PP; p = 0.006) and the Public/University groups (6.5 PP; p = 0.012), but not other groups. Practice characteristics may be critical factors in predicting intervention success.
- Open Access
- 31 July 2015
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 11 (2) , 123-131
Designing and Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials
Abstract: Objectives: African-Americans (AAs) have a high prevalence of hypertension and their blood pressure (BP) control on treatment still lags behind other groups. In 2004, NHLBI funded five projects that aimed to evaluate clinically feasible interventions to effect changes in medical care delivery leading to an increased proportion of AA patients with controlled BP. Three of the groups performed a pooled analysis of trial results to determine: 1) the magnitude of the combined intervention effect; and 2) how the pooled results could inform the methodology for future health-system level BP interventions. Methods: Using a cluster randomized design, the trials enrolled AAs with uncontrolled hypertension to test interventions targeting a combination of patient and clinician behaviors. The 12-month Systolic BP (SBP) and Diastolic BP (DBP) effects of intervention or control cluster assignment were assessed using mixed effects longitudinal regression modeling. Results: 2,015 patients representing 352 clusters participated across the three trials. Pooled BP slopes followed a quadratic pattern, with an initial decline, followed by a rise toward baseline, and did not differ significantly between intervention and control clusters: SBP linear coefficient = -2.60±0.21 mmHg per month, p Conclusion: Investigators planning behavioral trials to improve BP control in health systems serving AAs should plan for small effect sizes and employ a “run-in” period in which BP can be expected to improve in both experimental and control clusters.
- 31 July 2015
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 11 (2) , 123-131
Open AccessDesigning and Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials
Abstract: Objectives: African-Americans (AAs) have a high prevalence of hypertension and their blood pressure (BP) control on treatment still lags behind other groups. In 2004, NHLBI funded five projects that aimed to evaluate clinically feasible interventions to effect changes in medical care delivery leading to an increased proportion of AA patients with controlled BP. Three of the groups performed a pooled analysis of trial results to determine: 1) the magnitude of the combined intervention effect; and 2) how the pooled results could inform the methodology for future health-system level BP interventions. Methods: Using a cluster randomized design, the trials enrolled AAs with uncontrolled hypertension to test interventions targeting a combination of patient and clinician behaviors. The 12-month Systolic BP (SBP) and Diastolic BP (DBP) effects of intervention or control cluster assignment were assessed using mixed effects longitudinal regression modeling. Results: 2,015 patients representing 352 clusters participated across the three trials. Pooled BP slopes followed a quadratic pattern, with an initial decline, followed by a rise toward baseline, and did not differ significantly between intervention and control clusters: SBP linear coefficient = -2.60±0.21 mmHg per month, p Conclusion: Investigators planning behavioral trials to improve BP control in health systems serving AAs should plan for small effect sizes and employ a “run-in” period in which BP can be expected to improve in both experimental and control clusters.
- 20 June 2013
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 34 (2) , 449-456
Differences in the Association of Peripheral Insulin and Cognitive Function in Non-Diabetic Alzheimer's Disease Cases and Normal Controls
Insulin resistance increases the risk of cognitive impairment and dementia, but higher insulin levels may be cognitively protective after a diagnosis of Alzheimer's disease (AD). The role of peripheral insulin as a predictor of cognitive decline both
- 20 June 2013
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 34 (2) , 449-456
Differences in the Association of Peripheral Insulin and Cognitive Function in Non-Diabetic Alzheimer's Disease Cases and Normal Controls
Insulin resistance increases the risk of cognitive impairment and dementia, but higher insulin levels may be cognitively protective after a diagnosis of Alzheimer's disease (AD). The role of peripheral insulin as a predictor of cognitive decline both
- Open Access
- 15 May 2012
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 4 (3) , 16
Factors that influence survival in a probable Alzheimer disease cohort
Introduction: This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades. Methods: Time to death after symptom onset was determined in 641 probable AD patients who were evaluated annually until death or loss to follow-up, and information was entered into a longitudinal database. Date of death was available for everyone including those eventually lost. Baseline variables included age, sex, race, disease severity, a calculated index of rate of initial cognitive decline from symptom onset to cohort entry (pre-progression rate or PPR), years of education, and medical comorbidities (diabetes, hypertension, hyperlipidemia, coronary disease, cerebrovascular disease). Multivariable Cox proportional hazard regression analysis was used to analyze the baseline and/or time dependent association in Mini-mental Status Exam (MMSE) severity, Physical Self Maintenance Scale (PSMS), Persistency Index (PI) of exposure to antipsychotic and antidementia drugs, and psychotic symptoms (hallucinations, delusions) with mortality. Results: Baseline covariates significantly associated with increased survival were younger age (p = .0016), female sex (p = .0001), and a slower PPR (p < .0001). Overall disease severity at baseline, medical comorbidities, and education did not influence time to death. Time-dependent changes in antipsychotic drug use, development of psychotic symptoms, antidementia drug use, and observed MMSE change were not predictive. In the final model the only time-dependent covariate that significantly decreased survival was worsening of functional ability on the PSMS (hazard ratio = 1.10; CI: 1.07-1.11). Conclusions: In this large AD cohort survival is influenced by age, sex, and the development of functional disability during follow-up. The most important predictor of mortality was a faster rate of cognitive decline at the initial patient visit (PPR). The currently available antidementia drugs do not prolong survival in Alzheimer patients.
- 15 May 2012
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 4 (3) , 16
Open AccessFactors that influence survival in a probable Alzheimer disease cohort
Introduction: This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades. Methods: Time to death after symptom onset was determined in 641 probable AD patients who were evaluated annually until death or loss to follow-up, and information was entered into a longitudinal database. Date of death was available for everyone including those eventually lost. Baseline variables included age, sex, race, disease severity, a calculated index of rate of initial cognitive decline from symptom onset to cohort entry (pre-progression rate or PPR), years of education, and medical comorbidities (diabetes, hypertension, hyperlipidemia, coronary disease, cerebrovascular disease). Multivariable Cox proportional hazard regression analysis was used to analyze the baseline and/or time dependent association in Mini-mental Status Exam (MMSE) severity, Physical Self Maintenance Scale (PSMS), Persistency Index (PI) of exposure to antipsychotic and antidementia drugs, and psychotic symptoms (hallucinations, delusions) with mortality. Results: Baseline covariates significantly associated with increased survival were younger age (p = .0016), female sex (p = .0001), and a slower PPR (p < .0001). Overall disease severity at baseline, medical comorbidities, and education did not influence time to death. Time-dependent changes in antipsychotic drug use, development of psychotic symptoms, antidementia drug use, and observed MMSE change were not predictive. In the final model the only time-dependent covariate that significantly decreased survival was worsening of functional ability on the PSMS (hazard ratio = 1.10; CI: 1.07-1.11). Conclusions: In this large AD cohort survival is influenced by age, sex, and the development of functional disability during follow-up. The most important predictor of mortality was a faster rate of cognitive decline at the initial patient visit (PPR). The currently available antidementia drugs do not prolong survival in Alzheimer patients.